July 7th 2025
Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
IVBM Chair Summarizes Key Takeaways on Value-Based Oncology Care
Incorporating Discussions of Cannabis Use Into Oncology Care Visits
From Policy to Practice: NCCN Summit Explores Equity in the Cancer Workforce
When to Pause Before Recommending Cannabis to Patients With Cancer